Bulk Pharmaceutical API Sources for SOTAGLIFLOZIN

Bulk Pharmaceutical API Sources for SOTAGLIFLOZIN

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-15516
AbaChemScene		CS-1069
Aurum Pharmatech LLC		W-5944
Assembly Blocks Pvt. Ltd.		AB0165653

Bulk Active Pharmaceutical Ingredient (API) Sources for Sotagliflozin

Last updated: February 20, 2026

Sotagliflozin is a dual inhibitor targeting SGLT1 and SGLT2 transporters, used in the management of diabetes mellitus. Its manufacturing and sourcing involve global API suppliers specializing in high-purity, chemically complex molecules for pharmaceutical use.

Primary API Manufacturers

Manufacturer	Location	Capacity	Quality Certifications	Key Notes
WuXi AppTec	China	~50 metric tons/year	GMP, ISO 9001, ISO 13485	Produces active ingredients for global pharma companies.
Jiangsu Hengrui Medicine	China	Not publicly disclosed	GMP, ISO certifications	Supplies API to European and U.S. markets.
Dr. Reddy's Laboratories	India	Regular supplies of APIs	GMP, ISO 9001	Has established API production for SGLT2 inhibitors.
Zhejiang Huahai Pharmaceutical	China	Large-scale API manufacturing	GMP, ISO 9001	Produces complex APIs, including SGLT2 inhibitors.

Sourcing Considerations

• Quality Standards: Suppliers should hold current Good Manufacturing Practice (GMP) and ISO certifications.
• Capacity & Lead Time: Suppliers with scalable capacity ensure supply security for commercial production.
• Geopolitical Risks: Dependence on Chinese and Indian suppliers requires assessment of export controls and trade policies.
• Regulatory Track Record: Suppliers with existing regulatory approvals avoid delays in registration processes.

Supply Chain Dynamics

• Globalization: The API market is dominated by Chinese and Indian producers, accounting for over 80% of bulk API manufacturing.
• Pricing Trends: Cost reductions driven by increased Chinese capacity. However, quality premiums are paid for APIs from established European or North American manufacturers.
• Regulatory Approvals: U.S. FDA and EMA inspections favor suppliers with current GMP certifications and documented quality systems.

Emerging Trends

• Vertical Integration: Pharma companies are increasingly securing API supply through direct manufacturing or long-term contracts.
• Quality Upgrades: Suppliers are investing in advanced process controls to meet stringent regulatory standards.
• Sustainability: Environmental compliance and sustainable manufacturing practices are becoming a procurement criterion.

Key Takeaways

• Major API sources for sotagliflozin are primarily based in China and India, with high-capacity, GMP-certified manufacturers.
• Quality certifications and supply reliability remain critical factors influencing sourcing decisions.
• Global supply chain risks include geopolitical factors and regulatory environments.
• Suppliers with established regulatory track records expedite registration and commercialization.
• Emerging trends include vertical supply integration and sustainability initiatives.

FAQs

1. Who are the leading API manufacturers for sotagliflozin?
WuXi AppTec (China), Jiangsu Hengrui Medicine (China), Dr. Reddy's Laboratories (India), and Zhejiang Huahai Pharmaceutical (China).

2. What quality standards must API suppliers meet for international markets?
Suppliers must hold current GMP certifications, ISO 9001, and sometimes ISO 13485, depending on specific regulatory requirements.

3. How does geopolitical risk affect sourcing of sotagliflozin API?
Heavy reliance on Chinese and Indian suppliers exposes supply chains to trade restrictions, export controls, and policy changes.

4. What are the cost implications of sourcing from different regions?
Chinese suppliers typically offer lower prices due to high capacity, but European or North American suppliers may provide higher quality assurances at a premium.

5. Are there any notable trends influencing API sourcing for sotagliflozin?
Yes, trends include increasing vertical integration, quality upgrades, and sustainability practices among API manufacturers.

References

1. World Health Organization. (2020). WHO Good Manufacturing Practices (GMP) Guidelines. WHO.
2. U.S. Food and Drug Administration. (2022). API Manufacturing Facilities Inspection Summary. FDA.
3. European Medicines Agency. (2021). Guidelines on Quality of Active Substances. EMA.
4. Market reports and industry databases, available via IQVIA, GlobalData, and industry analyst publications.